Resumen

CADENA GARCIA, Juan Martín; GIRALDO MURILLO, Carlos Eduardo  y  RAMOS JARAMILLO, Manuela. EGFR and HER2 small molecules inhibitors as potential therapeutics in veterinary oncology. Rev. colomb. cienc. quim. farm. [online]. 2020, vol.49, n.2, pp.452-471.  Epub 23-Nov-2020. ISSN 0034-7418.  https://doi.org/10.15446/rcciquifa.v49n2.89898.

EGFR and HER2 receptors are crucial signaling molecules tyrosine kinase involved in human cancer. Aberrant signaling is associated with a variety of cancers, frequently with poor prognosis. Currently, EGFR and HER2 receptors are being targeted by small molecules, which offer a huge benefit to those patients afflicted by aggressive forms of cancer, improving their prognosis. Both human and canine cancers share molecular, biological, histopathological, and clinical similarities, including EGFR and HER2 expression in some forms of cancer. However, despite the use of one tyrosine kinase inhibitor approved to treat canine mastocytoma, canine cancers overexpressed EGFR and HER2 do not yet have targeted therapy, leading to high morbidity and mortality. Targeting EGFR and HER2 receptors in canine cancers using comparative approaches in human cancer could lead to better outcomes.

Palabras clave : Human cancer; veterinary cancer; EGFR; HER2; inhibitors.

        · resumen en Español     · texto en Inglés     · Inglés ( pdf )